Background. Taiwan's National Health Insurance (NHI) is a comprehensive and universal program, providing Western medicine (WM) and Chinese medicine (CM). This study aims to explore CM use among prostate cancer patients in NHI. Methods. A cross-section retrospective analysis was conducted using registration and claim data sets from the NHI Research Database. In 2007, 22 352 prostate cancer patients with 265 497 visits of CM and WM ambulatory services were identified. Patient demographics, patterns of therapies, and costs were analyzed. Results. In 2007, 592 prostate cancer patients (2.6%) had 4141 CM outpatient visits (7.0 on average). The median age was 73.9. The majority (90.5%) of CM users also used WM ambulatory services. About one third of CM outpatient services were provided by private clinics. The most frequently used CM therapies were Chinese herbal medication (93.6%), followed by acupuncture/traumatology manipulative therapies (7.0%). CM accounted for 0.2% expenditure ($87 500) and 1.6% visits of ambulatory services. The average cost per visit for WM was 6.3 times higher than that for CM ($133.6 vs $21). Conclusions. The prevalence and costs of insurance-covered CM among prostate cancer patients were low. Most prostate cancer patients did not use insurance-covered CM. The majority of CM users also used WM. CM appeared to play a complementary rather than an alternative role.
Introduction
In recent years, the use of complementary and alternative medicine (CAM) has increased, especially among oncology patients. [1] [2] [3] CAM comprises a diverse set of healing philosophies, therapies, and products. Traditional Chinese medicine (CM) is one of the most popular CAM modalities worldwide. Acupuncture and Chinese herbal medicine are well known and have been practiced in the West. [4] [5] [6] [7] In Chinese societies and East Asia, CM still plays an active role in the modern health system. [8] [9] [10] [11] [12] Prostate cancer is the most commonly diagnosed visceral cancer in the United States 13 and is the fifth most common cancer in Taiwan. 14 Previous studies demonstrated that CAM is popular among prostate cancer patients worldwide. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Yet little information exists about CAM use among prostate cancer patients in Taiwan. Because CM is the most important category of CAM in Taiwan, a large-scale study to explore the use of CM among prostate cancer patients is necessary.
In Taiwan, the National Health Insurance (NHI) system has provided a full range of care, from ambulatory and inpatient care to traditional CM, dental services, child delivery, rehabilitation, home care, and chronic psychiatric rehabilitation since 1995. The NHI covered more than 99% of Taiwan's 23-million population and 93% of medical institutes (23 478 contracted institutes). The NHI Research Database (NHIRD) provides all registration data sets and claim data sets for research. In this study, we use NHIRD to explore the prevalence, patterns, and costs of insurance-covered CM among prostate cancer patients. Use of Western medicine (WM) was also surveyed for comparison.
Materials and Methods Data Sources
A cross-sectional retrospective study was conducted using registration and claim data sets of the year 2007 from NHIRD. Files of registry for beneficiaries and ambulatory care expenditures by visits were obtained for analysis. To protect privacy, the data on patient identities and institutions were scrambled cryptographically by NHIRD. Institutional review board approval was not required for this study because all personal data were kept confidential by the NHIRD.
NHI only covered CM outpatient services but not inpatient services. Therefore, only CM and WM ambulatory services were analyzed in this study. The data element of ambulatory care expenditures by visits included an encounter form-based data set with date, time of visit, patient demographics (identifier, gender, date of birth), medical facility visited, department visited, prescribing physician, dispensing pharmacist, 3 items of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, case type, primary procedure (e.g. drug or diagnostic procedure), other procedures, type of copayment, and billed and paid amounts.
Study Sample
The participants of this study were identified from the NHIRD by a principal diagnosis of prostate cancer (ICD-9-CM codes: 185 and 185.0). In 2007, a total of 22 352 male patients with prostate cancer and 265 497 visits were identified from the file of ambulatory care expenditures by visits. To obtain demographic data, claim data of ambulatory care were linked with files of registry for beneficiaries by beneficiaries' identifications and birth dates.
Statistics
The database software ASIQ 12.5.7 (Sybase Inc, Dublin, CA) was used for data linking and processing. The data were analyzed using SPSS for Windows Version 13.0 (SPSS Inc, Chicago, IL). The distribution and frequency of each category of variables were examined by c 2 tests. A P value of less than .05 was considered statistically significant.
Results
A total of 22 352 prostate cancer patients used ambulatory services in 2007. Among them, 592 prostate cancer patients (2.6%) used CM outpatient services. Most CM users (90.5%) also used WM ambulatory services ( Figure 1 ).
User Demographics
The demographics are presented in Table 1 . The median age was 73.9 in CM users and 75.9 in nonusers. There was a higher portion of CM users than nonusers among participants in their 50s to 70s.
In terms of income (insured payroll-related amounts), there was no significant difference between CM users and nonusers. In terms of insured regions, there were a higher proportion of CM users registered in central and southern Taiwan. In terms of insured unit, there were a higher proportion of CM users who were dependent, although no significant difference was found.
Visit Frequency
In 2007, 592 prostate cancer patients accounted for 4141 CM outpatient visits (average 7.0 visits) and 22 296 patients accounted for 261 356 WM visits (average 11.7 visits). More than half of the CM users (64.0%) had fewer than 6 visits, 18.4% had 7 to 12 visits, and 17.6% had more than 12 visits in 2007. For WM users, 38.5% had fewer than 6 visits, 21.2% had 7 to 12 visits, and 40.3% had more than 12 visits. Those who were combined users of WM and CM had higher visit frequency than single modality users ( Figure 2 ).
Medical Institutes
Most ambulatory services of WM were provided by hospitals (93.6%). In contrast, 32.4% of CM outpatient services were provided by private clinics ( Table 2 ). The rest of the CM services were provided by general hospitals with a CM department (63.9%) and CM hospitals (3.7%). Private hospitals (44.0%) provided more CM services than public hospitals (19.9%) did.
Patterns of Therapies
The most frequently used CM therapies were Chinese herbal medication (93.6%), followed by acupuncture/ traumatology manipulative therapies (7.0%). In WM, the most frequently used services were outpatient services (97.1%), followed by emergency medicine (2.1%), home care (0.6%), outpatient surgery (0.1%), and dental care (0.01%).
Coexisting Diseases
All ambulatory claims data recorded 3 items of diagnosis in the ICD-9-CM format. The most frequently recorded coexisting disease was general symptoms(8.0%), followed by hypertension (5.1%), and functional digestive disorders (4.9%) among CM users ( 
Expenditure
The details of expenditure are shown in Table 4 . WM ambulatory services accounted for 98.4% of all visits and 99.8% of the total expenditure; CM outpatient services accounted for 1.6% of the visits and 0.2% of the expenditure. The fee for consultation, treatment, and medical supply and drugs for WM were much higher than those for CM. The average expenditure was NT$51 690. 9 
Discussion
This study is the first large-scale survey in the literature focusing on CM use among prostate cancer patients. In this study, the prevalence of insurance-covered CM use among prostate cancer patients who used ambulatory services was 2.6%. Because the NHI covered more than 99% of Taiwan's 23-million population and 93% of the medical institutes (23 478 contracted institutes), the NHI databases are representative of the general population. Subgroup populations usually excluded in other clinical trials, such as older people, children, and pregnant women, are all included in the NHI research databases.
The prevalence of CM in this study is much lower compared with previous small-scale studies, with 11.9% to 64% of CM use among cancer patients in Taiwan. [27] [28] [29] Several reasons might explain the findings: (1) strict definition of CM in this study, (2) the need for self-paid Chinese herbal medicines and services in this study population, and (3) the popularity of folk medicine in Taiwan. Liu's study 27 used a questionnaire with 64 cancer patients, and 64% of the patients admitted to using alternative Chinese medications at some time after the diagnosis of cancer. The definition of traditional medications in use included pills (small black pills) and powdered prescription in 5 (7.8%), Ling Chi with/without herbs in 39 (60.9%), pharmaceutical concoctions (bottled in vials) in 4 (6.3%), and combinations of the above in 16 patients (25.0%). The source of medication included Chinese medical clinic (with licensed practitioner) in 20 (31.2%), herb shop in 10 (15.6%), direct marketing/ gift in 30 (46.9%), and more than 1 source in 4 (6.3%). In Yang's face-to-face interview study 29 (n = 160), the prevalence of traditional CM was 9.4%, and the prevalence of acupuncture was 2.5%. Use of CM was restricted to prescriptions and treatment by licensed CM doctors. Patients who purchased Chinese herbal medicine from a traditional herb store without a prescription from a licensed CM doctor were considered to be users of biologically based therapies. In Pu's study, 28 a total of 2499 cancer patients were interviewed using a questionnaire, of which 2034 had full information and were analyzed. A total of 440 (21.6%) patients used traditional CM, and 110 (5.4%) patients used acupuncture. The definition of traditional CM included Chinese herbs, folk prescription (butter bean, Abrus In this study, only insurance-covered CM outpatient services practiced by licensed doctors of CM at NHI-contracted medical institutes were accounted for. Coverage of CM under the NHI includes extract CMs, acupuncture, moxibustion, and traumatology manipulative therapy. CM inpatient services were not covered by NHI except a pilot program for some diseases. Out-of-pocket CM services, herbals, and non-NHI contracted medical institutes were not included in this study. Besides, nonqualified or nonregulated folk medicines were not taken into account in this study. Folk medicine is very popular in Taiwan. In a previous survey of older people in one city in southern Taiwan, almost three fourths of the respondents reported the use of at least 1 CAM therapy (nonbiomedicine) during the past year, and 9% of the respondents were users of folk medicine modalities. 30 Although almost all the people in Taiwan are covered by National Health Insurance, there is still a higher demand for noncovered rather than covered CAM. Shih et al 31 performed a survey consisting of 10 600 noncovered and 9187 covered CAM users in Taiwan. In Shih's survey, 6.05% of respondents used noncovered CAM. The most frequently used types of CAM were chiropractic care and massage (44.70%), followed by folk remedies (35.63%), spiritual healing (23.39%), and bone setting and die-da sun shang (10.05%). In covered CAM, 4.95% of the respondents had used traditional Chinese herbal medicine, and 2.25% used acupuncture, moxibustion, and traumatology manipulative therapy.
The use of CAM varies by patients' cultural, religious, ethnic, gender, and geographic distributions. Previous studies revealed that the prevalence of CAM use among prostate cancer patients may range from 18% to 43% worldwide. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] CM has been popular in Taiwan since the 16th century when early Chinese immigrants brought it to Taiwan. 32 Thus, the prevalence of and patterns of use among Taiwanese CAM users may differ widely from those in Western countries. In previous studies of Western countries, CAM users with prostate cancer tend to be highly educated, with higher income, and with multiple comorbidities. In terms of income (insured payroll-related amounts) and insured unit, no significant difference between CM users and nonusers was found in this study. Because nonsalary income was not included in insured payroll-related amounts, this may underestimate the actual income. Furthermore, because insurance-covered CM is inexpensive, there is no barrier for prostate cancer patients with lower income to use CM.
This study found that there were a higher proportion of CM users in central and southern Taiwan. This is consistent with previous studies in Taiwan. 28 Past study also showed that "usable resources" was an important factor that influenced CM purchasing behavior. 33 Because Taipei is the capital and biggest city of Taiwan and located in the north of Taiwan Island, this area is more urban and modern than other parts of Taiwan. It affords greater accessibility to medical resources for people living in northern Taiwan. Besides, location could reflect differences in local culture. Taiwan is an island with quite a large variation in culture and socioeconomic status across the island. The development of Taiwan by Chinese immigrations was from south to north. Because CM is a traditional medicine in Chinese culture, patients in southern and central Taiwan might tend to prefer CM more than those in northern Taiwan.
With the resurgence of interest in CM in Taiwan, NHIcontracted CM institutes increased 62%, from 1722 to 2794, within 12 years. At the end of 2007, 22 hospitals with CM sections and 2772 CM clinics provided CM services. A previous study showed that most CM services were provided by clinics (82.6%) rather than hospitals. 34 However, our study found that 32.4% of CM visits of prostate cancer patients were provided by private clinics and 67.6% by hospitals, mostly by WM hospitals with CM sections rather than hospitals of CM. This reflects that CM users with prostate cancer may prefer to be treated at the same hospital where they received WM. Therefore, it is important to provide CM services in general hospitals for prostate cancer patients. Private hospitals (44.0%) provided more CM services than public hospitals (19.9%) did. Private hospitals seem to be more aggressive in responding to the needs of patients.
In this study, there was a higher proportion of WM visits with coexisting diseases. This might be attributed to CM users having less coexisting disease. However, because no CM inpatient service is available, patients with poor general condition will have little chance to visit CM outpatient facilities. Another explanation is that WM physicians tend to record more coexisting diseases under the NHI system. Because most WM services were provided by hospitals (93.6%), there will be more information for WM physicians to record coexisting diseases. Under NHI regulations, drugs, examinations, and treatments should only be paid with related diagnoses recorded in the ICD-9-CM format. Therefore, recorded diagnoses reflect the purpose for each visit. WM physicians have to record more coexisting diseases to give drugs, examinations, or treatments whereas CM physicians cannot use WM drugs, examinations, and treatments. Furthermore, one kind of CM might treat many kinds of diseases at the same time based on concepts different from WM. This study also found that the top 3 coexisting diseases of WM users were symptoms/disorders involving the urinary system, whereas those of CM users were not. This reflects the fact that prostate cancer patients mostly seek WM for urinary problems. A prostate cancer patient may visit the urology outpatient department most often. Therefore, urinary system diseases will be the most frequently recorded. In contrast, 86% of CM visits recorded prostate cancer as the only or the first diagnosis. It implies that most CM users with prostate cancer seek CM for their prostate cancer or cancer-related problems.
CM outpatient services accounted for only 1.6% of visits and 0.2% of the expenditure of ambulatory services among prostate cancer patients. Therefore, WM is the main choice for treatment. More than half of CM users (64.0%) had fewer than 6 visits, and 17.6% had more than 12 visits. For WM users, 38.5% had fewer than 6 visits, and 40.3% had more than 12 visits. Under NHI, patients are free to choose WM and CM services. WM and CM are popular and affordable in Taiwan. Past research on patient satisfaction has found a positive relationship between satisfaction and hospital use. 35 More than half of CM users (64.0%) had fewer than 6 visits, and this might reflect dissatisfaction with CM. In contrast, about one sixth of CM users were frequent CM outpatient visitors, and they might tend to be more satisfied. However, satisfaction depends on a number of factors. This group of patients also used WM frequently. Therefore, high use of CM might reflect the nature of the conditions being treated.
Several limitations of this study must be acknowledged. Out-of-pocket herbal medicine and noncontracted clinics were not investigated. For cancer patients, the need for rare and expensive Chinese herbal medicines, which were not covered in NHI, is high. Besides, some famous clinics are not contracted with NHI because the payment of NHI is low. The NHIRD data might thus lead to an underestimation of CM costs. The NHIRD is primarily for administrative purposes. Clinical characteristics, including staging, prostatespecific antigen (PSA), and biochemical data were thus not available in this study. The adverse effects of CM also need further investigation.
In conclusion, the prevalence and costs of insurancecovered CM among prostate cancer patients was low. Most prostate cancer patients did not use insurance-covered CM. The majority of CM users also used WM. CM appeared to play a complementary rather than an alternative role.
